Developer docs
API playgroundTry for free, no card

Search company profiles

Cullgen

Full company profile

uuid0003k6h

Namestring
Cullgen
Legal namestring
Cullgen Inc.
Websiteurl
cullgen.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Cullgen Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California, with research and development operations in Shanghai, China. The company develops targeted protein degrader therapies using its proprietary uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) platform, which harnesses the body's innate ubiquitin-proteasome system to destroy disease-causing proteins, including those previously considered 'undruggable' by traditional small molecule inhibitors. Cullgen's pipeline includes two clinical-stage candidates: CG001419, an oral pan-TRK degrader being evaluated in Phase 1 trials for both NTRK fusion-positive solid tumors and acute post-operative pain, and CG009301, a selective GSPT1 degrader for relapsed/refractory hematological malignancies. The company is also developing Degrader-Antibody Conjugates (DACs) as a next-generation ADC modality and has built proprietary novel E3 ligase ligands in-house rather than relying on common thalidomide-analog ligases.

Cullgen's business model is that of a pre-commercial biopharmaceutical company, with no product revenue. Revenue is derived from strategic partnership and licensing arrangements, most notably a 2023 collaboration and exclusive option agreement with Astellas Pharma Inc. that included $35M upfront, up to $85M upon license exercise, and potential milestones exceeding $1.9 billion plus royalties. The company has raised approximately $121M in equity financing across seed ($15M, GNI Group, 2018), Series A ($16M, Sequoia Capital China and HighLight Capital, 2019), Series B ($50M, 3E Bioventures-led, 2021), and Series C ($40M, AstraZeneca-CICC-led, 2023). Cullgen was acquired by Gyre Therapeutics in May 2026 in an approximately $300 million all-stock transaction, becoming a wholly-owned subsidiary that combines its U.S.-based R&D with Gyre's China-based commercial infrastructure. Cullgen's customer base consists of patients with cancer, pain, and inflammatory diseases, while its direct commercial counterparties are large pharmaceutical partners and equity investors.

Short descriptiontext

Cullgen is a clinical-stage biopharmaceutical company developing targeted protein degrader therapies using its proprietary uSMITE™ platform to treat cancer, pain, and inflammatory diseases. The company was acquired by Gyre Therapeutics in May 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, clinical-stage biopharmaceuticals, protein degrader therapeutics, ubiquitin-proteasome platform, degrader-antibody conjugates
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Clinical-stage targeted protein degradation therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Licensing Revenue
TypeLicensing Royalties
Description

Strategic collaborations with pharmaceutical companies generating upfront payments, milestone payments, and potential royalty payments on commercial sales. Examples include Astellas partnership with $35M upfront, up to $85M upon license exercise, and potential total exceeding $1.9B in milestones plus royalties.

cullgen.com
2Product Sales (Future)
TypeOne Time License
Description

Pre-commercial stage with no current product revenue. Upon regulatory approval, the company would generate revenue from product sales of targeted protein degraders for cancer, pain, and inflammatory diseases.

stocktitan.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cullgen is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degrader small-molecule therapeutics using its proprietary uSMITE™ platform. Its pipeline includes CG001419, an oral pan-TRK degrader in Phase 1 trials for solid tumors and acute post-operative pain, and CG009301, a GSPT1 degrader in a Phase 1 trial in China for relapsed/refractory hematological malignancies, supplemented by a Degrader-Antibody Conjugate (DAC) platform for antibody-directed cancer therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 trial showed all doses well-tolerated with no drug-related serious adverse events in 78 healthy volunteers
+2 more records
Product overview1 text field

Cullgen is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies using its proprietary uSMITE™ platform. The company's portfolio consists of two clinical-stage product candidates: CG001419, an oral pan-TRK degrader being developed for both solid tumors and pain management, and CG009301, a GSPT1 degrader for blood cancers. Cullgen also develops Degrader-Antibody Conjugates (DACs) as a next-generation delivery technology for cancer therapy. The company operates with R&D facilities in both San Diego, USA and Shanghai, China. Cullgen was acquired by Gyre Therapeutics in May 2026.

Product and service3 records
1uSMITE™ Platform
CategoryDrug discovery platform / technology platform
Description

Proprietary ubiquitin-mediated, small molecule-induced target elimination (uSMITE™) drug discovery platform that uses bifunctional small molecules to bind a disease-causing protein and recruit an E3 ligase, driving ubiquitination and proteasomal degradation of targets considered previously "undruggable" by traditional functional site inhibition. Used internally by Cullgen for pipeline generation and made available to partners through discovery collaborations.

2CG001419 (TRK Degrader)
CategoryClinical-stage oncology and pain product candidate
Description

First-in-class, selective, oral pan-tropomyosin receptor kinase (pan-TRK) protein degrader being evaluated in two separate Phase 1 trials: one in solid tumors with NTRK gene fusions (including NTRK fusion-positive cancers and wild-type TRK over-expression) and one in acute post-operative pain, designed as a non-opioid, non-NSAID analgesic therapy. Licensed to Astellas Pharma for further development and commercialization under the 2023 strategic collaboration.

3CG009301 (GSPT1 Degrader)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-06-14
Description

Strategic research collaboration and exclusive option agreement to discover multiple innovative protein degraders. Astellas provides $35M upfront, up to $85M upon license exercise, and potential total exceeding $1.9B in milestones plus royalties. Cullgen can participate in costs, profits, losses, and co-promote partnered products in the U.S. for lead program (cell cycle protein degrader for breast cancer and solid tumors).

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer and clinical leader in targeted protein degradation using PROTAC bifunctional degraders. Most directly comparable to Cullgen — both develop heterobifunctional small-molecule degraders leveraging the ubiquitin-proteasome system, with multiple clinical-stage oncology assets.

TypeDirect peer
Description

Clinical-stage biotech developing targeted protein degraders (PROTAC-based) across oncology and immunology indications. Comparable modality, target classes, and pipeline structure to Cullgen's uSMITE platform.

TypeDirect peer
Description

Clinical-stage company developing small-molecule degraders (including MonoDACs and bifunctional degraders) for cancer and neurodegenerative diseases. Directly competes with Cullgen in TPD modality and target space.

TypeDirect peer
Description

Develops targeted protein degraders and E3 ligase modulators using its DELigase platform, with multiple clinical-stage assets and major pharma partnerships (Sanofi, Gilead). Closely comparable TPD peer with similar partnership-driven business model.

TypeDirect peer
Description

Clinical-stage biotech developing molecular glue degraders leveraging cereblon and novel E3 ligases for cancer and immunology. Comparable modality and platform differentiation strategy to Cullgen's proprietary E3 ligand approach.

TypeDirect peer
Description

Develops therapeutics targeting the chromatin regulatory system, including protein degraders. Overlaps with Cullgen in applying TPD to 'undruggable' transcription factors and regulatory proteins.

TypeEmerging player
Description

Privately-held biotech combining chemoproteomics with targeted protein degradation to drug challenging targets. Comparable in approach of expanding the degradable target universe using proprietary ligase ligands.

TypeEmerging player
Description

Europe-based TPD company developing bifunctional degraders with novel mechanisms beyond traditional PROTACs. Comparable to Cullgen in exploring differentiated E3 ligase engagement.

TypeBroad incumbent
Description

Cullgen's largest pharma partner ($1.9B+ potential milestone package). Astellas is building internal TPD capabilities, making it both a customer and a broad incumbent exploring the same degrader space.

TypeBroad incumbent
Description

Major pharma investor via the AZ-CICC fund (led Cullgen's $40M Series C) with internal TPD programs and ADC franchise. Comparable as both a strategic investor and competing modality developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cullgen

Clinical-stage targeted protein degradation therapeuticscullgen.com

Cullgen is a clinical-stage biopharmaceutical company developing targeted protein degrader therapies using its proprietary uSMITE™ platform to treat cancer, pain, and inflammatory diseases. The company was acquired by Gyre Therapeutics in May 2026.

What Cullgen does

Cullgen Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California, with research and development operations in Shanghai, China. The company develops targeted protein degrader therapies using its proprietary uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) platform, which harnesses the body's innate ubiquitin-proteasome system to destroy disease-causing proteins, including those previously considered 'undruggable' by traditional small molecule inhibitors. Cullgen's pipeline includes two clinical-stage candidates: CG001419, an oral pan-TRK degrader being evaluated in Phase 1 trials for both NTRK fusion-positive solid tumors and acute post-operative pain, and CG009301, a selective GSPT1 degrader for relapsed/refractory hematological malignancies. The company is also developing Degrader-Antibody Conjugates (DACs) as a next-generation ADC modality and has built proprietary novel E3 ligase ligands in-house rather than relying on common thalidomide-analog ligases.

Cullgen's business model is that of a pre-commercial biopharmaceutical company, with no product revenue. Revenue is derived from strategic partnership and licensing arrangements, most notably a 2023 collaboration and exclusive option agreement with Astellas Pharma Inc. that included $35M upfront, up to $85M upon license exercise, and potential milestones exceeding $1.9 billion plus royalties. The company has raised approximately $121M in equity financing across seed ($15M, GNI Group, 2018), Series A ($16M, Sequoia Capital China and HighLight Capital, 2019), Series B ($50M, 3E Bioventures-led, 2021), and Series C ($40M, AstraZeneca-CICC-led, 2023). Cullgen was acquired by Gyre Therapeutics in May 2026 in an approximately $300 million all-stock transaction, becoming a wholly-owned subsidiary that combines its U.S.-based R&D with Gyre's China-based commercial infrastructure. Cullgen's customer base consists of patients with cancer, pain, and inflammatory diseases, while its direct commercial counterparties are large pharmaceutical partners and equity investors.

Cullgen firmographics

Firmographics
Name
Cullgen
Legal name
Cullgen Inc.
Website
https://cullgen.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cullgen is a clinical-stage biopharmaceutical company developing targeted protein degrader therapies using its proprietary uSMITE™ platform to treat cancer, pain, and inflammatory diseases. The company was acquired by Gyre Therapeutics in May 2026.
Ownership category
akta.pro rank

Cullgen industry classification

Industry
Product category
Clinical-stage targeted protein degradation therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Targeted protein degradation
  • Clinical-stage biopharmaceuticals
  • Protein degrader therapeutics
  • Ubiquitin-proteasome platform
  • Degrader-antibody conjugates

Where Cullgen is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cullgen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Partnership and Licensing Revenue: Strategic collaborations with pharmaceutical companies generating upfront payments, milestone payments, and potential royalty payments on commercial sales. Examples include Astellas partnership with $35M upfront, up to $85M upon license exercise, and potential total exceeding $1.9B in milestones plus royalties.
  2. Product Sales (Future): Pre-commercial stage with no current product revenue. Upon regulatory approval, the company would generate revenue from product sales of targeted protein degraders for cancer, pain, and inflammatory diseases.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Cullgen product offering

Product offering

Core offering

Cullgen is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degrader small-molecule therapeutics using its proprietary uSMITE™ platform. Its pipeline includes CG001419, an oral pan-TRK degrader in Phase 1 trials for solid tumors and acute post-operative pain, and CG009301, a GSPT1 degrader in a Phase 1 trial in China for relapsed/refractory hematological malignancies, supplemented by a Degrader-Antibody Conjugate (DAC) platform for antibody-directed cancer therapy.

Product overview

Cullgen is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies using its proprietary uSMITE™ platform. The company's portfolio consists of two clinical-stage product candidates: CG001419, an oral pan-TRK degrader being developed for both solid tumors and pain management, and CG009301, a GSPT1 degrader for blood cancers. Cullgen also develops Degrader-Antibody Conjugates (DACs) as a next-generation delivery technology for cancer therapy. The company operates with R&D facilities in both San Diego, USA and Shanghai, China. Cullgen was acquired by Gyre Therapeutics in May 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • uSMITE™ Platform Proprietary ubiquitin-mediated, small molecule-induced target elimination (uSMITE™) drug discovery platform that uses bifunctional small molecules to bind a disease-causing protein and recruit an E3 ligase, driving ubiquitination and proteasomal degradation of targets considered previously "undruggable" by traditional functional site inhibition. Used internally by Cullgen for pipeline generation and made available to partners through discovery collaborations.
  • CG001419 (TRK Degrader) First-in-class, selective, oral pan-tropomyosin receptor kinase (pan-TRK) protein degrader being evaluated in two separate Phase 1 trials: one in solid tumors with NTRK gene fusions (including NTRK fusion-positive cancers and wild-type TRK over-expression) and one in acute post-operative pain, designed as a non-opioid, non-NSAID analgesic therapy. Licensed to Astellas Pharma for further development and commercialization under the 2023 strategic collaboration.
  • CG009301 (GSPT1 Degrader)

Quantifiable outcome

  • Phase 1 trial showed all doses well-tolerated with no drug-related serious adverse events in 78 healthy volunteers
  • +2 more outcomes

Companies that use Cullgen

Customer profile

Segments4 records

Ideal customer profiles3 records

Cullgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cullgen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Astellas Pharma Inc.flagshipStrategic or Co-development Partner · 14 June 2023Strategic research collaboration and exclusive option agreement to discover multiple innovative protein degraders. Astellas provides $35M upfront, up to $85M upon license exercise, and potential total exceeding $1.9B in milestones plus royalties. Cullgen can participate in costs, profits, losses, and co-promote partnered products in the U.S. for lead program (cell cycle protein degrader for breast cancer and solid tumors).

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Cullgen competitors and assessment

Company assessment

Direct peers

  • Arvinas: Pioneer and clinical leader in targeted protein degradation using PROTAC bifunctional degraders. Most directly comparable to Cullgen — both develop heterobifunctional small-molecule degraders leveraging the ubiquitin-proteasome system, with multiple clinical-stage oncology assets.
  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders (PROTAC-based) across oncology and immunology indications. Comparable modality, target classes, and pipeline structure to Cullgen's uSMITE platform.
  • C4 Therapeutics: Clinical-stage company developing small-molecule degraders (including MonoDACs and bifunctional degraders) for cancer and neurodegenerative diseases. Directly competes with Cullgen in TPD modality and target space.
  • Nurix Therapeutics: Develops targeted protein degraders and E3 ligase modulators using its DELigase platform, with multiple clinical-stage assets and major pharma partnerships (Sanofi, Gilead). Closely comparable TPD peer with similar partnership-driven business model.
  • Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders leveraging cereblon and novel E3 ligases for cancer and immunology. Comparable modality and platform differentiation strategy to Cullgen's proprietary E3 ligand approach.
  • Foghorn Therapeutics: Develops therapeutics targeting the chromatin regulatory system, including protein degraders. Overlaps with Cullgen in applying TPD to 'undruggable' transcription factors and regulatory proteins.

Emerging players

  • Frontier Medicines: Privately-held biotech combining chemoproteomics with targeted protein degradation to drug challenging targets. Comparable in approach of expanding the degradable target universe using proprietary ligase ligands.
  • Amphista Therapeutics: Europe-based TPD company developing bifunctional degraders with novel mechanisms beyond traditional PROTACs. Comparable to Cullgen in exploring differentiated E3 ligase engagement.

Broad incumbents

  • Astellas Pharma: Cullgen's largest pharma partner ($1.9B+ potential milestone package). Astellas is building internal TPD capabilities, making it both a customer and a broad incumbent exploring the same degrader space.
  • AstraZeneca: Major pharma investor via the AZ-CICC fund (led Cullgen's $40M Series C) with internal TPD programs and ADC franchise. Comparable as both a strategic investor and competing modality developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cullgen social profiles

Digital presence

Cullgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cullgen leadership team

Management profile

Number of profiles

Profiles10 records

Cullgen funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cullgen M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cullgen

What does Cullgen do?

Cullgen is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degrader small-molecule therapeutics using its proprietary uSMITE™ platform. Its pipeline includes CG001419, an oral pan-TRK degrader in Phase 1 trials for solid tumors and acute post-operative pain, and CG009301, a GSPT1 degrader in a Phase 1 trial in China for relapsed/refractory hematological malignancies, supplemented by a Degrader-Antibody Conjugate (DAC) platform for antibody-directed cancer therapy.

Is Cullgen a public or private company?

Cullgen is a private company. It is classified as corporate owned and is currently acquired.

When was Cullgen founded?

Cullgen was founded in 2018. It employs 11 to 50 people.

Where is Cullgen based?

Cullgen is headquartered in San Diego, United States, in the North America region.

How does Cullgen make money?

Two revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are product Sales (Future).

Who are Cullgen's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, C4 Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics and Foghorn Therapeutics. Emerging players are Frontier Medicines and Amphista Therapeutics. Broad incumbents are Astellas Pharma and AstraZeneca.

Does Cullgen have an API?

No public API is recorded for Cullgen.

What industry is Cullgen in?

Cullgen's product category is Clinical-stage targeted protein degradation therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCoherus cuts 30% of staffers, Gyre makes post-acquisition layoffsCoherus Oncology is cutting 30% of its workforce, while Gyre Therapeutics is laying off an undisclosed number of employees after acquiring Cullgen. Coherus' cuts lower its quarterly core cash burn by $6 million, and Gyre's personnel costs rose $3.6 million in Q3 due to restructuring and severance.Quiver QuantitativeGYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens | GYRE Stock NewsGyre Therapeutics reported second-quarter 2026 revenue of $29.1 million, down from $29.7 million a year earlier, while GAAP net loss widened significantly to $14.3 million compared with a $2.2 million loss in Q2 2025. The company reaffirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million and highlighted two key developments: China's CDE accepted the NDA for F351 for CHB-induced liver fibrosis in May 2026, and the company closed its approximately $300 million all-stock acquisition of Cullgen in May 2026.YahooGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateGyre Therapeutics reported second-quarter 2026 revenue of $29.1 million and affirmed its full-year revenue guidance of $100.5 to $111.0 million. The company also announced that China's National Medical Products Administration accepted a New Drug Application for its pipeline candidate F351, while highlighting the acquisition of Cullgen.FinancialContent Business PageGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateGyre Therapeutics reported Q2 2026 revenue of $29.1 million, a 2% decrease year-over-year, with a net loss of $14.3 million compared to a $2.2 million loss in Q2 2025, driven by significantly higher R&D expenses and transaction costs. The company closed its acquisition of Cullgen Inc. in May 2026 for approximately $300 million in an all-stock transaction, gaining access to targeted protein degrader and DAC therapies for cancer and inflammatory diseases. China's Center for Drug Evaluation (CDE) accepted the NDA for F351 (hydronidone) for chronic hepatitis B-induced liver fibrosis in May 2026, with full-year 2026 revenue guidance of $100.5 to $111.0 million affirmed.Investing.comGyre Therapeutics stockholders approve all proposals at annual meeting By Investing.comGyre Therapeutics stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 10, including the election of two Class II directors and the ratification of Grant Thornton Zhitong as the company's independent auditor. The company's stock has declined 27% over the past year, trading at $5.86 with a market cap of $535 million, though it holds more cash than debt on its balance sheet. The article also notes recent developments including the company's completed acquisition of Cullgen Inc. for approximately $300 million and the appointment of Cullgen's former CEO, Dr. Ying Luo, as Gyre's new President and CEO.TipranksGyre Therapeutics Highlights Cullgen Acquisition and Pipeline ExpansionGyre Therapeutics planned to present a corporate and scientific update at a conference in Shanghai on May 15, 2026, highlighting its expanded pipeline and recent acquisition of protein degrader specialist Cullgen. The company outlined its strategy to integrate Cullgen's protein degrader platform with its China-based R&D capabilities and existing manufacturing and commercial infrastructure to develop degrader- and drug-antibody conjugate-based therapies for fibrosis, inflammatory diseases and solid tumors. The combined entity aims to position itself as a more formidable player in next-generation oncology and immunology therapeutics.Investing.comGyre Therapeutics CEO Luo Ying sells $82,927 in company stock By Investing.comGyre Therapeutics CEO Luo Ying sold 10,315 shares of company stock for approximately $82,927 on May 5–6, 2026, at prices between $8.01 and $8.04 per share, with the transactions executed under a pre-established Rule 10b5-1 trading plan through shares indirectly held by the CEO's spouse. The article notes the stock has since declined to $7.07, reflecting volatile trading with a beta of 5.28, with the CEO retaining indirect holdings of 2,565,226 shares following the sales. The article also references recent positive developments including the completion of Gyre's $300 million acquisition of Cullgen Inc. and a priority review status granted by China's NMPA for Gyre's Hydronidone liver fibrosis treatment.Stock TitanGyre Q1 Revenue $22.5M, Affirms 2026 OutlookGyre Therapeutics reported Q1 2026 revenue of $22.5 million, a 2% increase year-over-year, but swung to a net loss of $9.9 million from net income of $3.7 million in Q1 2025, driven by a $12.1 million increase in operating expenses including transaction costs and expanded marketing for new products. The company affirmed its full-year 2026 revenue guidance of $100.5 to $111.0 million and completed the approximately $300 million all-stock acquisition of Cullgen, expanding its pipeline into targeted protein degradation for inflammatory diseases and cancers. Gyre, through its majority-owned subsidiary Gyre Pharmaceuticals, also submitted an NDA for F351 to China's CDE seeking conditional approval for CHB-associated liver fibrosis treatment.GlobeNewswireGyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateGyre Therapeutics reported Q1 2026 revenue of $22.5 million and a net loss of $9.9 million. It affirmed full-year 2026 revenue guidance of $100.5–111.0 million and submitted an NDA for F351 for CHB-associated liver fibrosis to China's CDE. The company also completed its acquisition of Cullgen in an approximately $300 million all-stock transaction.Stock TitanGyre Therapeutics Closes $300M Cullgen DealGyre Therapeutics announced the closing of its acquisition of Cullgen Inc. in an all-stock transaction valued at approximately $300 million, effective May 4, 2026. Following the acquisition, Cullgen became a wholly owned subsidiary of Gyre, and Cullgen's former CEO Dr. Ying Luo was appointed President and CEO of the combined company. The new entity operates as a U.S.- and China-based fully integrated biopharmaceutical company with a commercial-stage product (ETUARY® for lung fibrosis in China), a Phase 3 candidate (F351 for liver fibrosis), and a pipeline of targeted protein degrader therapies.